2Traynor BJ,Codd MB,Corr B,et al.Clinical features of amyotrophic lateral sclerosis according to the E1 Escorial and Airlie House diagnostic critefia:a population-based study. Arch Neurol, 2000,57:1171.
4Chalabi A,Anderson PM, Chioza B, et al, Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder, evidence for a linked protective factor.Hun Mol Genet,1998,7:2045.
5Rowland LP. Molecular basis of genetic heterogeneity:role of the clinical neurologist. J Child Neurol, 1998,13:122.
6Anderson PM,Nilsson P,Keranen ML,et al.Phenotypic heterogeneity in motor neuron disease patients with Cu Zn-superoxide dismutase mutations in Scandinavia. Brain,1997,120:1723.
7Berger MM,Kopp N,Vital C,et al.Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS, Neurology,2000,54:20.
8Apple S. ALS: immune factors in motor neuron cell injury. In:Neurobiology of ALS:education program syllabus.Amerlcan Academy of Neurology, 1999,1:101.
9Estevez AG,Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosls in motor neurons by zine-deficient superoxide dismutase. Science, 1999,286:2498.
10Cleveland DW,Liu J. Oxidation versus aggregation-how do SOD1 mutants cause ALS? Nat Med,2000,6:1320.
3Miller RG,Munsat TL,Swash M,et al. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research.J Neurol Sci, 1999,169( 1/2 ):2-12.
4Mills KR, Nithi KA. Peripheral and central motor conduction in amyotrophic lateral sclerosis.J Neurol Sci, 1998,159( 1 ):82-87.
5Eisen A, Swash M. Clinical neurophysiology of ALS.Clin Neurophysiol, 2001,112(12):2190-2201.
